Product Description
novel siRNA-based therapeutic, bevasiranib, for the treatment of wet AMD. Bevasiranib is believed to work by down regulating VEGF production in the retina. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661434/)
Mechanisms of Action: VEGF Inhibitor
Novel Mechanism: No
Modality: Nucleic Acid
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: OPKO Health
Company Location: MIAMI FL 33137
Company CEO: Phillip Frost
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Macular Degeneration|Choroidal Neovascularization
Phase 2: Choroidal Neovascularization|Macular Degeneration|Macular Edema
Phase 1: Macular Degeneration
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CARBON | P3 |
Withdrawn |
Macular Degeneration |
2011-07-01 |
|
| COBALT | P3 |
Terminated |
Choroidal Neovascularization|Macular Degeneration |
2010-08-12 |
|
| COBALT | P3 |
Terminated |
Macular Degeneration |
2009-03-01 |
|
| ACU201 | P2 |
Completed |
Choroidal Neovascularization|Macular Degeneration |
2007-12-01 |